The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart. RESULTS: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern. CONCLUSIONS: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of CATT participants (>92%) had stable or improved VA relative to baseline.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Comparison of AMD Treatments Trials (CATT) showed that bevacizumab was equivalent to ranibizumab in improving visual acuity (VA) of patients with neovascular AMD when treatment was administered either monthly or pro re nata (PRN).1”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this remarkable clinical effect, there was a wide range in treatment response.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“At one year, participants treated monthly with bevacizumab or ranibizumab gained 8.0 and 8.5 letters, respectively, and those treated as needed gained 5.9 and 6.8 letters, respectively.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,134
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,009
Ranibizumab for age-related macular degeneration
Dhoot, D. S., & Kaiser, P. K. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.660523 · Cited by 54
Fung, A. T.-C., Kumar, N., Vance, S. K., Slakter, J. S., Klancnik, J. M., Spaide, R. F., & Freund, K. B. (2012) · Eye · doi:10.1038/eye.2012.174 · Cited by 54
Virgili, G., Parravano, M., Menchini, F., & Brunetti, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub3 · Cited by 54
Ciulla, T. A., Pollack, J. S., & Williams, D. F. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317337 · Cited by 54
Suppression of myeloid PFKFB3‐driven glycolysis protects mice from choroidal neovascularization
Liu, Z., Mao, X., Yang, Q., Zhang, X., Xu, J., Ma, Q., Zhou, Y., Da, Q., Cai, Y., Sopeyin, A., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15925 · Cited by 52
Moon, B., Kim, Y., & Kim, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613004 · Cited by 53
Role of microglia/macrophage polarisation in intraocular diseases (Review)
Li, H., Li, B., & Zheng, Y. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5369 · Cited by 56
Age-Related Macular Degeneration Preferred Practice Pattern®
Vemulakonda, G. A., Bailey, S. T., Kim, S. J., Kovach, J. L., Lim, J. I., Ying, G., & Flaxel, C. J. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.12.018 · Cited by 56
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
Kimoto, K., & Kubota, T. (2011) · Journal of Ophthalmology · doi:10.1155/2012/852183 · Cited by 54
Aflibercept in wet age-related macular degeneration: a perspective review
Ohr, M. P., & Kaiser, P. K. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312446007 · Cited by 53
Singer, M. A., Herro, A. M., Probandarwalla, S. S., Pollard, J., Amir, A., Herro, & Singer (2011) · Clinical ophthalmology · doi:10.2147/opth.s15028 · Cited by 51
Zinc Supplementation Inhibits Complement Activation in Age-Related Macular Degeneration
Smailhodzic, D., van Asten, F., Blom, A. M., Mohlin, F. C., den Hollander, A. I., van de Ven, J. P. H., van Huet, R. A. C., Groenewoud, J. M. M., Tian, Y., Berendschot, T. T. J. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112682 · Cited by 54
Grunwald, J. E., Daniel, E., Ying, G., Pistilli, M., Maguire, M. G., Alexander, J., Martin, R., Parker, C., Sepielli, K., Blodi, B. A., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.013 · Cited by 53
Shin, H. J., Kim, S., Chung, H., Kim, T., & Kim, H. C. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18404 · Cited by 54
Nguyen, C. L., Oh, L. J., Wong, E. H., Wei, J., & Chilov, M. N. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0785-3 · Cited by 55
Pharmacological Advances in the Treatment of Age-related Macular Degeneration
Gil‐Martínez, M., Santos-Ramos, P., Fernández-Rodríguez, M., Abraldes, M. J., Rodríguez‐Cid, M. J., Santiago-Varela, M., Fernández‐Ferreiro, A., & Gómez‐Ulla, F. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190726121711 · Cited by 54
Biosimilars for Retinal Diseases: An Update
Sharma, A., Kumar, N., Parachuri, N., Bandello, F. M., Kuppermann, B. D., & Loewenstein, A. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.11.017 · Cited by 53
Mantel, I. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.3.6 · Cited by 51
Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels
Ablonczy, Z., Dahrouj, M., & Marneros, A. G. (2014) · The FASEB Journal · doi:10.1096/fj.13-248021 · Cited by 52
Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization
Introini, U., Casalino, G., Querques, G., Gimeno, A. T., Scotti, F., & Bandello, F. M. (2012) · Eye · doi:10.1038/eye.2012.75 · Cited by 52
Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration
Frampton, J. E. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0077-9 · Cited by 53
Kumar, N., Mrejen, S., Fung, A. T.-C., Marsiglia, M., Loh, B. K., & Spaide, R. F. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.076 · Cited by 53
Freund, K. B., Balaratnasingam, C., Dhrami‐Gavazi, E., McCann, J., & Ghadiali, Q. (2015) · Clinical ophthalmology · doi:10.2147/opth.s80040 · Cited by 55
Increased VEGF‐A promotes multiple distinct aging diseases of the eye through shared pathomechanisms
Marneros, A. G. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505613 · Cited by 51
Involvement of B cells in non‐infectious uveitis
Smith, J. R., Stempel, A. J., Bharadwaj, A. S., & Appukuttan, B. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.2 · Cited by 52
Vaze, A., Fraser‐Bell, S., & Gillies, M. C. (2014) · Retina · doi:10.1097/iae.0000000000000173 · Cited by 52
Safety and complications of intravitreal injections performed in an Asian population in Singapore
Xu, Y., & Tan, C. S. (2016) · International Ophthalmology · doi:10.1007/s10792-016-0241-4 · Cited by 52
Nanoceria‐loaded injectable hydrogels for potential age‐related macular degeneration treatment
Wang, K., Mitra, R. N., Zheng, M., & Han, Z. (2018) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36450 · Cited by 53
Bandello, F. M., Augustin, A. J., Tufail, A., & Leaback, R. (2018) · European Journal of Ophthalmology · doi:10.1177/1120672117750058 · Cited by 52
Overview of age-related ocular conditions.
Akpek, E. K., & Smith, R. A. (2013) · PubMed · Cited by 52
Evaluation of Pain in Intravitreal Bevacizumab Injections
Moisseiev, E., Regenbogen, M., Bartfeld, Y., & Barak, A. (2012) · Current Eye Research · doi:10.3109/02713683.2012.681335 · Cited by 51
Williams, T. A., & Blyth, C. P. (2011) · Eye · doi:10.1038/eye.2011.224 · Cited by 50
Melo, G. B., Figueira, A. C. M., Batista, F. A. H., Filho, A. A. S. L., Rodrigues, E. B., Belfort, R., & Maia, M. (2019) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20190503-05 · Cited by 51
Altaweel, M. M., Daniel, E., Martin, D. F., Mittra, R. A., Grunwald, J. E., Lai, M. M., Melamud, A., Morse, L. S., Huang, J., Ferris, F. L., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.020 · Cited by 51
KSI-301: antibody biopolymer conjugate in retinal disorders
Chandrasekaran, P. R., & Madanagopalan, V. (2021) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414211027708 · Cited by 52
Diabetic Macular Edema and Diode Subthreshold Micropulse Laser
Lois, N., Campbell, C., Waugh, N. R., Azuara‐Blanco, A., Maredza, M., Mistry, H., McAuley, D. F., Acharya, N., Aslam, T. M., Bailey, C., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.08.012 · Cited by 53
Ng, B., Kolli, H., Ajith-Kumar, N., Azzopardi, M., Logeswaran, A., Buensalido, J., Mushtaq, B., Chavan, R., & Chong, Y. J. (2024) · Life · doi:10.3390/life14020193 · Cited by 53
Wu, Y., Chang, C., Kao, A., Hsi, B., Lee, S., Chen, Y., & Wang, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126750 · Cited by 51
Chae, B., Jung, J. J., Mrejen, S., Gallego‐Pinazo, R., Yannuzzi, N. A., PATEL, S. N., Chen, C. Y., Marsiglia, M., Boddu, S., & Freund, K. B. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16494 · Cited by 49
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians
Keane, P. A., & Sadda, S. R. (2011) · Journal of Ophthalmology · doi:10.1155/2012/483034 · Cited by 51
Cloutier, F., Lawrence, M. S., Goody, R. J., Lamoureux, S., Al-Mahmood, S., Colin, S., Ferry, A., Conduzorgues, J.-P., Hadri, A., Cursiefen, C., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-9064 · Cited by 51
Huang, L., Li, Y., Xie, X., Zhang, J., Cheng, C., Yamashiro, K., Chen, L., Ma, X., Cheung, C. M. G., Wang, Y.-S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7687 · Cited by 51
Eleftheriadou, M. I., Vázquez-Alfageme, C., Citu, M. C., Crosby‐Nwaobi, R., Sivaprasad, S., Hykin, P. G., HAMILTON, R. D., & Patel, P. J. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.09.038 · Cited by 51
Soares, R. R., Mellen, P. L., Garrigan, H., Obeid, A., Wibbelsman, T. D., Borkar, D. S., Ho, A. C., & Hsu, J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.07.010 · Cited by 51
Hackett, S. F., Fu, J., Kim, Y. C., Tsujinaka, H., Shen, J., Silva, R. L. E., Khan, M., Hafiz, Z., Wang, T., Shin, M. D., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119935 · Cited by 51
SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT
Chhablani, J. K., Narayanan, R., Mathai, A., Yogi, R., & Stewart, M. (2015) · Retina · doi:10.1097/iae.0000000000000913 · Cited by 50
Reiter, G. S., Grechenig, C., Vogl, W., Guymer, R. H., Arnold, J., Bogunović, H., & Schmidt-Erfurth, U. M. (2020) · Retina · doi:10.1097/iae.0000000000003023 · Cited by 50
Cheung, C. M. G., Bhargava, M., Laude, A., Koh, A. C., Xiang, L., Wong, D., Niang, T., Lim, T. H., Gopal, L., & Wong, T. Y. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2012.02765.x · Cited by 50
Ocular Pharmacokinetics of Bevacizumab in Vitrectomized Eyes with Silicone Oil Tamponade
Xu, Y. H., You, Y., Du, W., Zhao, C., Li, J., Mao, J., Chen, H., & Cheng, L. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9702 · Cited by 50
Nowomiejska, K., Oleszczuk, A., Brzozowska, A., Grzybowski, A. E., Książek, K., Maciejewski, R., Książek, P., Juenemann, A. G. M., & Ręjdak, R. (2013) · BMC Ophthalmology · doi:10.1186/1471-2415-13-13 · Cited by 50
Oliver, V. F., Franchina, M., Jaffe, A. E., Branham, K. E. H., Othman, M., Heckenlively, J. R., Swaroop, A., Campochiaro, B., Vote, B. J. T., Craig, J. E., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.042 · Cited by 50
Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Romano, M. R., & Costagliola, C. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.911284 · Cited by 52
Kim, J. H., Chang, Y. S., & Kim, J. W. (2017) · Retina · doi:10.1097/iae.0000000000001494 · Cited by 50
Chen, J., Wang, W., & Li, Q. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484907 · Cited by 50
Mantel, I., Gillies, M. C., & Souied, E. H. (2018) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2018.02.004 · Cited by 49
Wang, H., Wittchen, E. S., Jiang, Y., Ambati, B. K., Grossniklaus, H. E., & Hartnett, M. E. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8230 · Cited by 51
Seguin‐Greenstein, S., Lightman, S., & Tomkins‐Netzer, O. (2016) · Journal of Ophthalmology · doi:10.1155/2016/4095852 · Cited by 50
Bressler, N. M., Veith, M., Hamouz, J., Ernest, J., Zalewski, D., Studnička, J., Vajas, A., Papp, A., Vogt, G., Luu, J. K., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319637 · Cited by 49
Bing, G., Liu, J., Li, X., Ma, Q., Shen, M., & Cheng, L. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16597 · Cited by 49
Drug delivery techniques for treating age-related macular degeneration
Schwartz, S. G., Scott, I. U., Flynn, H. W., & Stewart, M. W. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.859135 · Cited by 50
Klufas, M. A., & Chan, R. V. P. (2015) · Journal of Pediatric Ophthalmology & Strabismus · doi:10.3928/01913913-20150216-01 · Cited by 49
Maruko, I., Iida, T., Oyamada, H., Sugano, Y., Ojima, A., & Sekiryu, T. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.03.041 · Cited by 49
Monés, J., Leiva, M., Peña, M. T., Martı́nez, G., Biarnés, M., Garcia, M., Serrano, A., & Fernández, E. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19355 · Cited by 50
A novel peptide specifically binding to VEGF receptor suppresses angiogenesis in vitro and in vivo
Zhang, Y., He, B., Liu, K., Lin, N., Luo, D., Xu, K., Zhu, W., Wu, Z., Huang, J. H., & Xu, X. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.10 · Cited by 49
Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration
Jackson, T. L., Chakravarthy, U., Slakter, J. S., Muldrew, A., Shusterman, E. M., O’Shaughnessy, D., Arnoldussen, M. E., Gertner, M. E., Danielson, L., & Moshfeghi, D. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.043 · Cited by 49
Stewart, M. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10010021 · Cited by 49
Fu, D. J., Faes, L., Wagner, S. K., Moraes, G., Chopra, R., Patel, P. J., Balaskas, K., Keenan, T. D. L., Bachmann, L. M., & Keane, P. A. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.01.009 · Cited by 48
Iatrogenic ophthalmic artery occlusion and retinal artery occlusion
Lee, J. S., Kim, J. Y., Jung, C., & Woo, S. J. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100848 · Cited by 48
Grant, C. L., Caromile, L. A., Durrani, K., Rahman, M., Claffey, K. P., Fong, G., & Shapiro, L. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041285 · Cited by 50
Bevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?
Avery, R. L. (2012) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2011.11.002 · Cited by 48
Liang, M. C., de Carlo, T. E., Baumal, C. R., Reichel, E., Waheed, N. K., Duker, J. S., & Witkin, A. J. (2016) · Retina · doi:10.1097/iae.0000000000001102 · Cited by 48
Siedlecki, J., Wertheimer, C. M., Wolf, A., Liegl, R. G.-H., Priglinger, C., Priglinger, S. G., & Eibl-Lindner, K. H. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3595-z · Cited by 47
Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics
Sokullu, E., Abyaneh, H. S., & Gauthier, M. A. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050211 · Cited by 48
Management and Outcomes for Neovascular Age-Related Macular Degeneration
Kiss, S., Campbell, J. H., Almony, A., Shih, V., Serbin, M., LaPrise, A., & Wykoff, C. C. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.02.027 · Cited by 49
Disease progression pathways of wet AMD: opportunities for new target discovery
Wolf, A. T., Harris, A., Oddone, F., Siesky, B. A., Vercellin, A. C. V., & Ciulla, T. A. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2030706 · Cited by 47
Sim, S. Y., Chalkiadaki, E., Koutsocheras, G., Nicholson, L., Sivaprasad, S., Patel, P. J., Selvam, S., Pal, B., Keane, P. A., Bhatia, B., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.07.020 · Cited by 50
Quality of bevacizumab compounded for intravitreal administration
Palmer, J. M., Amoaku, W. M. K., & Kamali, F. (2013) · Eye · doi:10.1038/eye.2013.139 · Cited by 47
Lai, T. Y. Y., & Fong, A. H. C. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s36811 · Cited by 50
Preclinical Investigations of Intravitreal Ziv-Aflibercept
Dias, J. R. D. O., Badaró, E., Novais, E. A., Colicchio, D., Chiarantin, G. M. D., da Palma, M. M., Verna, C., Penha, F. M., Barros, N. M. T., Meyer, C. H., et al. (2014) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20141118-15 · Cited by 47
Kirchhof, S., Abrami, M., Messmann, V., Hammer, N., Göpferich, A. M., Grassi, M., & Brandl, F. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00375 · Cited by 47
Dumoulin, C. L., Morin, M., Mayrand, M., Tousignant, M., & Abrahamowicz, M. (2017) · Trials · doi:10.1186/s13063-017-2261-4 · Cited by 47
Brynskov, T., Munch, I. C., Larsen, T. M., Erngaard, L., & Sørensen, T. L. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14183 · Cited by 46
Oxidative stress‐induced angiogenesis is mediated by miR‐205‐5p
Oltra, M. R., Vidal‐Gil, L., Maisto, R., Sancho-Pellúz, J., & Barcia, J. M. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14822 · Cited by 47
Maruko, I., Ogasawara, M., Yamamoto, A., Itagaki, K., Hasegawa, T., Arakawa, H., Nakayama, M., Koizumi, H., Okada, A. A., Sekiryu, T., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.03.010 · Cited by 46
Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update
Parravano, M., Costanzo, E., Scondotto, G., Trifirò, G., & Virgili, G. (2021) · BioDrugs · doi:10.1007/s40259-021-00499-2 · Cited by 48
Preferred therapies for neovascular age-related macular degeneration
Lally, D. R., Gerstenblith, A. T., & Regillo, C. D. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328352411c · Cited by 47
Ying, G., Maguire, M. G., Daniel, E., Grunwald, J. E., Ahmed, O. M., & Martin, D. F. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.046 · Cited by 45
A watertight acrylic-free titanium recording chamber for electrophysiology in behaving monkeys
Adams, D. L., Economides, J. R., Jocson, C. M., Parker, J. M., & Horton, J. C. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00405.2011 · Cited by 46
Tarallo, V., & Falco, S. D. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.04.008 · Cited by 47
Gray Hyper-Reflective Subretinal Exudative Lesions in Exudative Age-Related Macular Degeneration
Orès, R., Puche, N., Querques, G., Blanco-Garavito, R., Merle, B. M. J., COSCAS, G. J., Oubraham, H., Semoun, O., & Souied, E. H. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.04.025 · Cited by 46
Gomi, F., Sawa, M., Tsujikawa, M., & Nishida, K. (2012) · Retina · doi:10.1097/iae.0b013e31825be87f · Cited by 45
Lee, A., Lee, C. S., Egan, C. A., Bailey, C., Johnston, R. L., Natha, S., HAMILTON, R. D., Khan, R. S., Al‐Husainy, S., Brand, C., et al. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309818 · Cited by 46
Berkowitz, S. T., Sternberg, P., Feng, X., Chen, Q., & Patel, S. N. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.1971 · Cited by 48
Droho, S., Thomson, B. R., Makinde, H. M., Cuda, C. M., Perlman, H., & Lavine, J. A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02010-0 · Cited by 46
Rowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 46
Aflibercept for the Treatment of Age-Related Macular Degeneration
Trichonas, G., & Kaiser, P. K. (2013) · Ophthalmology and Therapy · doi:10.1007/s40123-013-0015-2 · Cited by 46
Gianniou, C., Dirani, A., Ferrini, W., Marchionno, L., Decugis, D., Deli, A., Ambresin, A., & Mantel, I. (2014) · Eye · doi:10.1038/eye.2014.258 · Cited by 44
Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases
Ventrice, P., Leporini, C., Aloe, J. F., Greco, E., Leuzzi, G., Marrazzo, G., Scorcia, G. B., Bruzzichessi, D., Nicola, V., & Scorcia, V. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.120947 · Cited by 46
Muthumani, K., Flingai, S., Wise, M. C., Tingey, C., Ugen, K. E., & Weiner, D. B. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26498 · Cited by 46
Hermann, M. M., van Asten, F., Muether, P. S., Smailhodzic, D., Lichtner, P., Hoyng, C. B., Kirchhof, B., Grefkes, C., den Hollander, A. I., & Fauser, S. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.047 · Cited by 45
Metadata
- Authors
- The CATT Research Group
- Corresponding author
- The CATT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-19
- Volume
- 364
- Issue
- 20
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3157322
- OpenAlex
- W1481978003
- Cited by
- 2,669
- References
- 21
- Citations by year
- 2026: 78 · 2025: 91 · 2024: 116 · 2023: 111 · 2022: 127 · 2021: 164 · 2020: 195 · 2019: 151 · 2018: 168 · 2017: 177 · 2016: 199 · 2015: 238 · 2014: 264 · 2013: 248 · 2012: 265
- FWCI
- 254.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, U10EY017823, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, ranibizumab, bevacizumab, intravitreal injection, anti-VEGF therapy, visual acuity, central retinal thickness, treatment schedule, non-inferiority, serious adverse events, off-label drug use, anti-angiogenic therapy, comparative efficacy and safety, hospitalization
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cardiovascular Diseases, Drug Administration Schedule, Female, Humans, Macular Degeneration, Male, Middle Aged, Retina, Therapeutic Equivalency, Visual Acuity, Proportional Hazards Models, Single-Blind Method, Off-Label Use, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
